Latest Conference Articles

89Zr-DFO-girentuximab May Improve Identification, Risk Stratification of Renal Tumors

Findings from the phase 3 ZIRCON trial showed that imaging with 89Zr-DFO-girentuximab could improve the identification and risk stratification of patients with renal tumors.

Apalutamide Plus ADT Improves PSA PFS in Biochemically Relapsed Prostate Cancer

Apalutamide plus androgen deprivation therapy with or without abiraterone acetate and prednisone improved prostate-specific antigen progression-free survival in patients with biochemically relapsed prostate cancer, according to long-term follow-up data from the phase 3 PRESTO trial.

Dr Daneschmand on Data From SunRISe-1 With TAR-200 and Cetrelimab in BCG-Unresponsive NMIBC

Sia Daneshmand MD, discusses preliminary results from the phase 2 SunRISe-1 trial (NCT04640623) in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Dr Saad on PSA Response and Time to PSA Progression With Abiraterone Acetate and Olaparib in mCRPC

Fred Saad, MD, FRCS, discusses prostate-specific antigen (PSA) response and time to PSA progression with the combination of abiraterone acetate and olaparib in patients with metastatic castration-resistant prostate cancer.

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

TAR-200 Produces High CR Rates, Tolerability in BCG-unresponsive NMIBC

Treatment with TAR-200 produced complete responses and was well tolerated in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer, according to preliminary data from the phase 2b SunRISe-1 trial.

Nivolumab Maintains DFS Benefit in MIUC and MIBC After Radical Surgery

Nivolumab following radical surgery continued to display a benefit in disease-free survival in patients with muscle-invasive urothelial carcinoma and muscle-invasive bladder cancer.

Sintilimab Plus Axitinib Has Clinical Efficacy in Advanced FH-Deficient RCC

Treatment with sintilimab in combination with axitinib resulted in tumor shrinkage with tolerable adverse effects in patients with advanced fumarate hydratase–deficient renal cell carcinoma.

Complications Following Partial Nephrectomy Associated With Particular Comorbidities in RCC

Specific comorbidities were linked with complications following partial nephrectomy, compared with radical nephrectomy, in patients with T1b to T2 renal cell carcinoma.

Hypertension Linked With Worse Outcomes for Patients With Upper Tract Urothelial Cancer Undergoing Nephroureterectomy

Hypertension was found to be an independent risk factor for worse survival outcomes in patients with upper tract urothelial cancer undergoing radical nephroureterectomy.

High BMI Associated With Longer OS in Patients With RCC Undergoing Nephrectomy

A high body mass index was linked with improved overall survival in patients with renal cell carcinoma undergoing radical nephrectomy.

Dr Lowentritt on PSA Response and Time to Castration Resistance in mCSPC

Benjamin H. Lowentritt, MD, FACS, discusses prostate-specific antigen response and time to castration resistance in patients with metastatic castration-sensitive prostate cancer started on apalutamide, enzalutamide, or abiraterone acetate.

Dr Li on the Use of CG0070 Plus Pembrolizumab in BCG-Unresponsive Non–muscle Invasive Bladder Cancer

Roger Li, MD, discusses phase 2 data with the combination of CG0070 and pembrolizumab in patients with non–muscle invasive bladder cancer unresponsive to Bacillus Calmette-Guérin.

Enzalutamide With or Without Leuprolide Offers MFS Benefit Vs Leuprolide Alone in nmHSPC With High-risk BCR

Treatment with the androgen receptor inhibitor enzalutamide plus leuprolide led to a significant reduction in the risk of metastasis or death compared with placebo plus leuprolide in patients with nonmetastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence.

Apalutamide Demonstrates Robust Real-World Effectiveness in mCSPC

Patients with metastatic castration-sensitive prostate cancer treated with the androgen receptor–signaling inhibitor apalutamide achieved prostate-specific antigen responses that trended higher and rates of progression to castration resistance that trended lower than those receiving enzalutamide or abiraterone acetate/

Darolutamide Plus ADT/Docetaxel Produces Durable PSA Responses in mHSPC

A post-hoc analysis of the phase 3 ARASENS trial demonstrated that the addition of darolutamide to androgen deprivation therapy and docetaxel produced deep and durable prostate-specific antigen responses in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide Plus ADT Elicits OS Benefit in North American Patients With mHSPC

A subgroup analysis of the phase 3 ARASENS trial showed that darolutamide plus androgen deprivation therapy elicited an overall survival benefit in North American patients with metastatic hormone-sensitive prostate cancer.

Phase 2 Data Show Clinical Activity With CG0070 Plus Pembrolizumab in NMIBC

Cretostimogene grenadenorepvec in combination with pembrolizumab produced high complete response rates with a tolerable safety profile in patients with Bacillus Calmette-Guérin–unresponsive non–muscle invasive bladder cancer.

Darolutamide Associated With Lower Rates of Treatment Discontinuation and Disease Progression in nmCRPC

Treatment with darolutamide was associated with lower rates of discontinuation and progression to metastatic disease compared with enzalutamide and apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

Long-Term JAVELIN Bladder 100 Data Support Avelumab Maintenance in Advanced Urothelial Carcinoma

First-line avelumab maintenance therapy prolonged survival in patients with advanced urothelial carcinoma, regardless of response to first-line chemotherapy, according to findings from an exploratory subgroup analysis of the phase 3 JAVELIN Bladder 100 trial.

68Ga-FAP-2286 PET Imaging Influences Bladder Cancer Treatment Decisions

The use of 68Ga-FAP-2286 PET imaging may improve treatment selection and response assessment in patients with bladder cancer, according to findings from a pilot study evaluating the diagnostic performance of this imaging technology.

Dr Basin on Pharmacological Inhibition of Hsp70 in Belzutifan-Resistant RCC

Michael Basin, MD, discusses how the pharmacological inhibition of the molecular chaperone Hsp70 overcomes belzutifan resistance in clear cell renal cell carcinoma.

Dr Katims on the Utility of the MSK-ACCESS Assay in Node+ MIBC

Andrew Katims, MD, MPH, discusses the utility of a circulating tumor DNA assay (MSK-ACCESS) in patients with node-positive muscle-invasive bladder cancer.

Frontline Olaparib Plus Abiraterone Reduces PSA Levels, Delays Time to PSA Progression in mCRPC

The addition of olaparib to abiraterone acetate resulted in numerically higher prostate-specific antigen response rates and prolonged time to PSA progression vs abiraterone alone when used in the frontline treatment of patients with metastatic castration-resistant prostate cancer.

Extended Darolutamide Demonstrates Long-term Safety, Clinical Benefit in Nonmetastatic CRPC

Darolutamide given in an extended duration was linked with long-term clinical benefit and safety in patients with nonmetastatic castration-resistant prostate cancer.

Apalutamide Dose Reduction Does Not Significantly Reduce Skin-related AEs in Advanced Prostate Cancer

Reduced doses of apalutamide did not significantly decrease rates of skin-related adverse effects vs full-dose apalutamide in patients with advanced prostate cancer.

177Lu-PSMA-I&T Generates PSA Responses With Tolerable Safety in mCRPC

Treatment with lutetium 177 PSMA-I&T radioligand therapy led to prostate-specific antigen declines with an acceptable toxicity profile in patients with metastatic castration-resistant prostate cancer.

Zoledronic Acid Lowers Risk of Fracture in mHSPC  

The use of zoledronic acid or other bisphosphonates was associated with a significant reduction in risk of fracture in patients with metastatic hormone-sensitive prostate cancer.

Novel Methylation-Based Platform Shows Promise for Multicancer Early Detection

A genome-wide methylome enrichment platform demonstrated efficacy in detecting early-stage, low-shedding cancers with limited circulating tumor DNA.

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.